MedTrace Logo

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00080340 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2008-01-15

No results posted yet for this study

Summary

The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Carcinoma

Interventions

DRUG

TLK286 (Telcyta) HCl for Injection

DRUG

gefitinib (Iressa)

Sponsors & Collaborators

  • Telik

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2005-05-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Chile
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00080340 on ClinicalTrials.gov